High Lipoprotein(a) Levels Signal Decades of Heart Risk

Long-term data in healthy women suggest targeted screening could identify those at greatest lifetime cardiovascular danger.

Thirty-year follow-up from a large cohort of healthy women shows that very high lipoprotein(a) levels strongly predict future heart disease, supporting selective screening to identify individuals who may benefit from early preventive car

Study Details

Lipoprotein(a), often written as Lp(a), has long been recognized as a genetically driven cholesterol particle linked to atherosclerosis. Unlike LDL cholesterol, Lp(a) levels are largely fixed at birth and are minimally influenced by diet, exercise, or weight loss.

The new analysis draws on nearly three decades of follow-up from the Women’s Health Study, a landmark cohort that enrolled initially healthy women in the early 1990s. Researchers examined whether commonly discussed clinical thresholds of lipoprotein(a) meaningfully predicted long-term cardiovascular outcomes.

This question matters because current cardiology guidelines generally stop short of recommending universal lipoprotein(a) screening, largely due to the absence of proven therapies that specifically lower Lp(a) and reduce events.

Methodology

Investigators analyzed baseline lipoprotein(a) levels in 27,748 women who were free of cardiovascular disease at enrollment. Participants were followed for a median of almost 28 years.

Outcomes included major adverse cardiovascular events, coronary heart disease, ischemic stroke, and cardiovascular death. Analyses adjusted for traditional risk factors such as age, blood pressure, smoking, diabetes, and standard cholesterol measures.

A genetic subanalysis examined carriers of a known LPA gene variant associated with higher lipoprotein(a) levels.

Key Findings

• Cardiovascular risk rose in a stepwise fashion as lipoprotein(a) levels increased, beginning around 30 to 60 mg/dL.

• Women with very high lipoprotein(a) levels above 120 mg/dL or in the top percentile had roughly 50 to 75 percent higher long-term risk of major cardiovascular events.

• The strongest associations were seen for coronary heart disease, suggesting heart attacks drive much of the excess risk.

• Mild to moderately elevated lipoprotein(a) levels were not associated with large increases in stroke or cardiovascular death.

• Carriers of a high-risk LPA genetic variant had higher rates of major cardiovascular events compared with non carriers.

Implications for Practice

For patients, this study reinforces that lipoprotein(a) is not just another lab value but a marker of lifelong cardiovascular risk. Individuals with very high levels may benefit from earlier and more aggressive prevention strategies, including tighter control of LDL cholesterol, blood pressure, and other modifiable risks.

For clinicians, the findings strengthen the case for targeted lipoprotein(a) testing, particularly in patients with a family history of premature heart disease or unexplained cardiovascular events. While lifestyle changes do not substantially lower lipoprotein(a), identifying high-risk individuals can guide intensity of preventive therapy and long-term monitoring.

Importantly, these results also arrive as lipoprotein(a)-lowering drugs are advancing in clinical development. If future trials confirm that lowering Lp(a) reduces heart attacks, prior screening could become a critical step in identifying patients most likely to benefit.